Investments
27Portfolio Exits
10About PBM Capital Group
PBM Capital Group is a private investment firm primarily focused on healthcare investments. The PBM Capital Group partners with exceptional scientists, engineers and entrepreneurs who have developed game-changing technology that can improve and save the lives of millions of people. The goal is to create financially strong companies that change the way we live our lives through science, innovation, and creativity. PBM creates value by applying extensive industry knowledge and contacts, providing superior operational expertise and bringing entrepreneurial spirit to attractive investment opportunities.
PBM Capital Group Headquarter Location
200 Garrett Street Suite P
Charlottesville, Virginia, 22902,
United States
434-980-8100
Expert Collections containing PBM Capital Group
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find PBM Capital Group in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Latest PBM Capital Group News
Jun 29, 2020
Jun. 29, 2020 4:19 PM ET Liquidia Technologies (NASDAQ: LQDA ) has agreed to acquire privately held RareGen, LLC , a portfolio company of PBM Capital Group, in a all-stock transaction. The Durham, NC-based pharma firm recently launched a generic version of treprostinil, in partnership with Novartis (NYSE: NVS ) unit Sandoz, for the treatment of pulmonary arterial hypertension. Concurrently, LQDA has launched a public offering of common stock. Price, volume and terms have yet be be announced.
PBM Capital Group Investments
27 Investments
PBM Capital Group has made 27 investments. Their latest investment was in Saliogen Therapeutics as part of their Series B on December 12, 2021.
PBM Capital Group Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
12/7/2021 | Series B | Saliogen Therapeutics | $115M | No | 3 | |
9/9/2021 | Series B | LEXEO Therapeutics | $100M | No | 9 | |
8/24/2021 | Series C | Xalud Therapeutics | $30M | No | 11 | |
2/18/2021 | Series A | |||||
2/9/2021 | Growth Equity |
Date | 12/7/2021 | 9/9/2021 | 8/24/2021 | 2/18/2021 | 2/9/2021 |
|---|---|---|---|---|---|
Round | Series B | Series B | Series C | Series A | Growth Equity |
Company | Saliogen Therapeutics | LEXEO Therapeutics | Xalud Therapeutics | ||
Amount | $115M | $100M | $30M | ||
New? | No | No | No | ||
Co-Investors | |||||
Sources | 3 | 9 | 11 |
PBM Capital Group Portfolio Exits
10 Portfolio Exits
PBM Capital Group has 10 portfolio exits. Their latest portfolio exit was Nanoview Biosciences on May 04, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
5/4/2022 | Acquired | 1 | |||
7/27/2021 | IPO | Public | 9 | ||
2/4/2021 | IPO | Public | 23 | ||
Date | 5/4/2022 | 7/27/2021 | 2/4/2021 | ||
|---|---|---|---|---|---|
Exit | Acquired | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 1 | 9 | 23 |
PBM Capital Group Acquisitions
2 Acquisitions
PBM Capital Group acquired 2 companies. Their latest acquisition was AkaRx on May 17, 2016.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
5/17/2016 | Series A | $12.5M | Acq - Fin | 1 | ||
2/5/2014 |
Date | 5/17/2016 | 2/5/2014 |
|---|---|---|
Investment Stage | Series A | |
Companies | ||
Valuation | ||
Total Funding | $12.5M | |
Note | Acq - Fin | |
Sources | 1 |
PBM Capital Group Team
6 Team Members
PBM Capital Group has 6 team members, including current Founder, Chief Executive Officer, Paul Manning.
Name | Work History | Title | Status |
|---|---|---|---|
Paul Manning | Founder, Chief Executive Officer | Current | |
Sean Stalfort | Benevolent Capital | President | Current |
Kevin Combs | Executive Vice President | Current | |
Jayson Rieger | Precigen, Forest Laboratories, Clinical Data, and Adenosine Therapeutics | Senior Vice President | Current |
Damian deGoa | Managing Director | Current |
Name | Paul Manning | Sean Stalfort | Kevin Combs | Jayson Rieger | Damian deGoa |
|---|---|---|---|---|---|
Work History | Benevolent Capital | Precigen, Forest Laboratories, Clinical Data, and Adenosine Therapeutics | |||
Title | Founder, Chief Executive Officer | President | Executive Vice President | Senior Vice President | Managing Director |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.